Citations (70)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Hareer Fatima, Hussain Sohail Rangwala, Muhammad Saqlain Mustafa, Muhammad Ashir Shafique, Syed Raza Abbas, Azra Rizwan, Tagwa Kalool Fadlalla Ahmed & Ainan Arshad. (2023) Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis. Diabetes, Metabolic Syndrome and Obesity 16, pages 3567-3578.
Read now
Read now
André J Scheen. (2023) Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?. Expert Review of Clinical Pharmacology 16:11, pages 1053-1062.
Read now
Read now
Ryan A. Lafferty, Peter R. Flatt & Nigel Irwin. (2023) GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opinion on Pharmacotherapy 24:5, pages 587-597.
Read now
Read now
Corrine I Voils, Kara L Gavin, Carolyn T Thorpe, Samantha K Pabich, Bryce B Reeve, Ghazan J Mian, Aaron Faacks & Ian M Kronish. (2022) Validating a Self-Reported Medication Nonadherence Measure in the Context of Multiple Chronic Diseases and Routes of Medication Administration Among Patients with Type 2 Diabetes. Patient Preference and Adherence 16, pages 3119-3130.
Read now
Read now
Tracy J Sims, Kristina S Boye, Susan Robinson & Tessa Kennedy-Martin. (2022) Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors. Patient Preference and Adherence 16, pages 1919-1939.
Read now
Read now
Kristina S Boye, Shraddha Shinde, Tessa Kennedy-Martin, Susan Robinson & Vivian T Thieu. (2022) Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review. Patient Preference and Adherence 16, pages 23-39.
Read now
Read now
Sean Wharton, Melanie Davies, Dror Dicker, Ildiko Lingvay, Ofri Mosenzon, Domenica M. Rubino & Sue D. Pedersen. (2022) Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine 134:1, pages 14-19.
Read now
Read now
Maka Siamashvili & Stephen N. Davis. (2021) Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology 14:9, pages 1081-1089.
Read now
Read now
. (2021) Removal Statement. Current Medical Research and Opinion 37:1, pages i-i.
Read now
Read now
Javier Morales, Jay H. Shubrook & Neil Skolnik. (2020) Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgraduate Medicine 132:8, pages 687-696.
Read now
Read now
Agostino Consoli, Gloria Formoso, Maria Pompea Antonia Baldassarre & Fabrizio Febo. (2018) A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opinion on Drug Safety 17:3, pages 293-302.
Read now
Read now
Articles from other publishers (59)
L. Yu. Khamnueva & L. S. Andreeva. (2023) Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus. Problems of Endocrinology 69:2, pages 38-46.
Crossref
Crossref
Xiaohui Guo, Wenying Yang, Junqing Zhang, Xiaolin Dong, Ming Liu, Shenghong Gu, Felipe Lauand, Lingyu Li, Qiong Huang, Lei Kang & Elisabeth Souhami. (2023)
iGlarLixi
provides a higher derived time‐in‐range versus insulin glargine 100
U
/
mL
or lixisenatide in
Asian Pacific
people with type 2 diabetes: A post hoc analysis
. Diabetes, Obesity and Metabolism.
Crossref
Crossref
Soumyabrata RoyChaudhuri, Anirban Majumder, Debmalya Sanyal, Soma Chakraborty & Susama Chuyan. (2023) Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?. Cureus.
Crossref
Crossref
Peyton W. Moore, Kevin Malone, Delena VanValkenburg, Lauren L. Rando, Brooke C. Williams, Hannah G. Matejowsky, Shahab Ahmadzadeh, Sahar Shekoohi, Elyse M. Cornett & Alan D. Kaye. (2022) GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. Advances in Therapy 40:3, pages 723-742.
Crossref
Crossref
Mohammad Sadiq Jeeyavudeen, Shahanas KA Khan, Sherouk Fouda & Joseph M Pappachan. (2023) Management of metabolic-associated fatty liver disease: The diabetology perspective. World Journal of Gastroenterology 29:1, pages 126-143.
Crossref
Crossref
David Seung U. Lee & Howard Lee. (2022) Adherence and persistence rates of major antidiabetic medications: a review. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
Meng Yu, Zheng Yang, Chongxin Chen, Yuhuan Lv, Linyu Xiang, Subei Zhao & Rong Li. (2022) Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
Timothy S. Bailey, Jasvinder Gill, Merwyn Jones S., Laxmi Shenoy, Charlie Nicholls & Jukka Westerbacka. (2022)
Real‐world outcomes of addition of insulin glargine 300 U/
mL
(Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The
DELIVER‐G
study
. Diabetes, Obesity and Metabolism 24:8, pages 1617-1622.
Crossref
Crossref
M. Ghidewon, H.S. Wald, A. D. McKnight, B. C. De Jonghe, D. M. Breen, A. L. Alhadeff, T. Borner & H. J. Grill. (2022)
Growth differentiation factor 15 (
GDF15
) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms
. Diabetes, Obesity and Metabolism 24:6, pages 1010-1020.
Crossref
Crossref
Rishav Adhikari, Kunal Jha, Zeina Dardari, James Heyward, Roger S. Blumenthal, Robert H. Eckel, G. Caleb Alexander & Michael J. Blaha. (2022) National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020. Journal of the American Heart Association 11:9.
Crossref
Crossref
Jing Luo, Nico Gabriel, Mary Korytkowski, Inmaculada Hernandez & Walid F. Gellad. (2022) Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. Diabetes Research and Clinical Practice 187, pages 109855.
Crossref
Crossref
Lavinia Boccia, Tito Borner, Misgana Y. Ghidewon, Patricia Kulka, Chiara Piffaretti, Sarah A. Doebley, Bart C. De Jonghe, Harvey J. Grill, Thomas A. Lutz & Christelle Le Foll. (2022) Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons. Molecular Metabolism 58, pages 101444.
Crossref
Crossref
Awadhesh Kumar Singh, Ritu Singh & Anoop Misra. (2022) Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:3, pages 102436.
Crossref
Crossref
Elizabeth Holmes‐Truscott, Jasmine Schipp, Trisha Dunning, John Furler, Virginia Hagger, Edith E. Holloway, Jo‐Anne Manski‐Nankervis, Jonathan E. Shaw, Timothy Skinner & Jane Speight. (2021) ‘For me, it didn’t seem as drastic a step as being controlled by insulin’: A qualitative investigation of expectations and experiences of non‐insulin injectable therapy among adults with type 2 diabetes. Diabetic Medicine 39:2.
Crossref
Crossref
Tito Borner, Ian C. Tinsley, Robert P. Doyle, Matthew R. Hayes & Bart C. De Jonghe. (2021) Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. British Journal of Pharmacology 179:4, pages 542-556.
Crossref
Crossref
Ben Jones. (2021) The therapeutic potential of GLP‐1 receptor biased agonism. British Journal of Pharmacology 179:4, pages 492-510.
Crossref
Crossref
Sean Wharton, Salvatore Calanna, Melanie Davies, Dror Dicker, Bryan Goldman, Ildiko Lingvay, Ofri Mosenzon, Domenica M. Rubino, Mette Thomsen, Thomas A. Wadden & Sue D. Pedersen. (2021) Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism 24:1, pages 94-105.
Crossref
Crossref
Kamran Qureshy, Andreas Ross Kirk, Michael Lyng Wolden, Amir Abbas Mohseni Zonoozi & Aiden Liu. (2022) A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada. Cardiovascular Endocrinology & Metabolism 11:2.
Crossref
Crossref
Riley Merkel, Amanda Moreno, Yafang Zhang, Rachel Herman, Jennifer Ben Nathan, Sana Zeb, Suditi Rahematpura, Kamryn Stecyk, Brandon T. Milliken, Matthew R. Hayes, Robert P. Doyle & Heath D. Schmidt. (2021) A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors. Neuroscience & Biobehavioral Reviews 131, pages 1169-1179.
Crossref
Crossref
Rory J. McCrimmon, Mark Lamotte, Mafalda Ramos, Abdul Jabbar Omar Alsaleh, Elisabeth Souhami & Elisheva Lew. (2021) Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy. Diabetes Therapy 12:12, pages 3231-3241.
Crossref
Crossref
Tito Borner, Caroline E. Geisler, Samantha M. Fortin, Richard Cosgrove, Jorge Alsina-Fernandez, Mridula Dogra, Sarah Doebley, Marcos J. Sanchez-Navarro, Rosa M. Leon, Jane Gaisinsky, Arianna White, Ankur Bamezai, Misgana Y. Ghidewon, Harvey J. Grill, Richard C. Crist, Benjamin C. Reiner, Minrong Ai, Ricardo J. Samms, Bart C. De Jonghe & Matthew R. Hayes. (2021) GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models. Diabetes 70:11, pages 2545-2553.
Crossref
Crossref
Federico Rea, Stefano Ciardullo, Laura Savaré, Gianluca Perseghin & Giovanni Corrao. (2021) Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting. Diabetes Research and Clinical Practice 180, pages 109035.
Crossref
Crossref
Joanna Van, Juan P. Frias, Enzo Bonora, Sohini Raha, Jarrett Meyer, Heike Jung, David Cox, Manige Konig, Jennifer Peleshok & M. Angelyn Bethel. (2021) Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. Diabetes Therapy 12:10, pages 2783-2794.
Crossref
Crossref
Matthew R. Hayes, Tito Borner & Bart C. De Jonghe. (2021) The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. Diabetes 70:9, pages 1956-1961.
Crossref
Crossref
Ricardo J. Samms, Kyle W. Sloop, Fiona M. Gribble, Frank ReimannAlice E. Adriaenssens. (2021) GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders. Diabetes 70:9, pages 1938-1944.
Crossref
Crossref
Ahmed M. Younes, Basem M. Mishriky, James R Powell & Doyle M Cummings. (2021) The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials. Diabetes Research and Clinical Practice 177, pages 108878.
Crossref
Crossref
Ricardo J. Samms, Michael E. Christe, Kyla A.L. Collins, Valentina Pirro, Brian A. Droz, Adrienne K. Holland, Jessica L. Friedrich, Samantha Wojnicki, Debra L. Konkol, Richard Cosgrove, Ellen P.S. Conceição Furber, Xiaoping Ruan, Libbey S. O’Farrell, Annie M. Long, Mridula Dogra, Jill A. Willency, Yanzhu Lin, Liyun Ding, Christine C. Cheng, Over Cabrera, Daniel A. Briere, Jorge Alsina-Fernandez, Ruth E. Gimeno, Julie S. Moyers, Tamer Coskun, Matthew P. Coghlan, Kyle W. Sloop & William C. Roell. (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation 131:12.
Crossref
Crossref
Søren Snitker, Andreas Andersen, Birgitte Berg, Sjoerd van Marle & Thomas Sparre. (2021) Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects. Diabetes, Obesity and Metabolism 23:6, pages 1415-1419.
Crossref
Crossref
William Polonsky, Cory Gamble, Neeraj Iyer, Mona Martin & Carol Hamersky. (2021) Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study. Diabetes Spectrum 34:2, pages 175-183.
Crossref
Crossref
Surekha Kattaru, Sunitha Manne Mudhu, Samundeshwari Echambadi Loganathan, Sireesha Kodavala & Venkata Gurunadha Krishna Sarma Potukuchi. (2021) Increased insulin and GLUT2 gene expression and elevated glucokinase activity in β-like cells of islets of langerhans differentiated from human haematopoietic stem cells on treatment with Costus igneus leaf extract. Molecular Biology Reports 48:5, pages 4477-4485.
Crossref
Crossref
Kristina Boye, Melissa Ross, Reema Mody, Manige Konig & Heather Gelhorn. (2020)
Patients' preferences for
once‐daily
oral versus
once‐weekly
injectable diabetes medications: The
REVISE
study
. Diabetes, Obesity and Metabolism 23:2, pages 508-519.
Crossref
Crossref
Wenfei Han & Ivan E. de Araujo. (2021) Nausea and the Brain: The Chemoreceptor Trigger Zone Enters the Molecular Age. Neuron 109:3, pages 391-393.
Crossref
Crossref
Hitoshi Ishii, Brian B. Hansen, Jakob Langer & Hiroshi Horio. (2021) Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial. Diabetes Therapy 12:2, pages 613-623.
Crossref
Crossref
Chelsea Baker, Cimmaron Retzik-Stahr, Vatsala Singh, Renee Plomondon, Victoria Anderson & Neda Rasouli. (2021) Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882098022.
Crossref
Crossref
Christopher K. Rayner, Tongzhi Wu, Vanita R. Aroda, Craig Whittington, Steve Kanters, Patricia Guyot, Alka Shaunik & Michael Horowitz. (2020)
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist
s
in people with type 2 diabetes mellitus: A network meta‐analysis
. Diabetes, Obesity and Metabolism 23:1, pages 136-146.
Crossref
Crossref
Francesco Giorgino, Irene Caruso & Raffaele Napoli. (2020) Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 170, pages 108478.
Crossref
Crossref
Philip D. Home, Vanita R. Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik, Mir Sohail Fazeli, Hardik Goswami, Sanjay Kalra & Mir‐Masoud Pourrahmat. (2020)
Efficacy and safety of
iGlarLixi
versus
IDegLira
in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison
. Diabetes, Obesity and Metabolism 22:11, pages 2170-2178.
Crossref
Crossref
Antonio C. Bossi, Valentina De Mori, Cristiana Scaranna, Giovanni Veronesi, Giuseppe Lepore, Agosti Barbara, Bellante Rosalia, Belviso Antonio, Berzi Denise, Bonfadini Silvia, Casati Sergio, Colzani Milena, Ettori Stefano, Franzetti Ivano, Gaiti Margherita, Ghilardi Giosuè, Lovati Elisabetta, Lucotti Pietro, Malighetti Maria Elena, Manzoni Giuseppina, Meregalli Giancarla, Orsi Emanuela, Palmieri Eva, Querci Fabrizio, Ragni Giorgio, Rinaldi Joselita, Severgnini Silvia Cecilia, Zenoni Luca, Bertola Davide Pietro, Buizza Mario, Calebitch Silvia, Creanza Annalisa, D’Angelo Francesco, Magri Viviana, Mantovani Linneo Enzo, Mascadri Cristina, Pagani Micol, Paroli Antonio, Richini Donata, Rignanese Giovanni & Zarra Emanuela. (2020) ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide. Diabetes Therapy 11:11, pages 2677-2690.
Crossref
Crossref
Raquel Herrera Comoglio & Xavier Vidal Guitart. (2020) Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs): A systematic review and meta‐analysis of observational cohort studies. International Journal of Clinical Practice 74:9.
Crossref
Crossref
Yun Kyung Cho, Jiwoo Lee, Hwi Seung Kim, Joong-Yeol Park, Chang Hee Jung & Woo Je Lee. (2020) Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study. Diabetes Therapy 11:9, pages 2029-2039.
Crossref
Crossref
In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang & Young Chul Sung. (2020)
A glycosylated
Fc
‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
. Diabetes, Obesity and Metabolism 22:8, pages 1455-1468.
Crossref
Crossref
Markolf Hanefeld, Holger Fleischmann, Thorsten Siegmund & Jochen Seufert. (2020) Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Therapy 11:8, pages 1645-1666.
Crossref
Crossref
Tito Borner, Jayme L. Workinger, Ian C. Tinsley, Samantha M. Fortin, Lauren M. Stein, Oleg G. Chepurny, George G. Holz, Aleksandra J. Wierzba, Dorota Gryko, Ebba Nexø, Evan D. Shaulson, Ankur Bamezai, Valentina A. Rodriguez Da Silva, Bart C. De Jonghe, Matthew R. Hayes & Robert P. Doyle. (2020) Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis. Cell Reports 31:11, pages 107768.
Crossref
Crossref
Francesco Giorgino, Irene Caruso, Julia Moellmann & Michael Lehrke. (2020) Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 104, pages 154045.
Crossref
Crossref
Hannah Gardner & Osama Hamdy. (2020) Oral GLP1 Analog: Where Does the Tide Go?. Clinical Medicine Insights: Endocrinology and Diabetes 13, pages 117955142098413.
Crossref
Crossref
K. Winkley, R. Upsher, W. H. Polonsky & E. Holmes‐Truscott. (2019) Psychosocial aspects and contributions of behavioural science to medication‐taking for adults with type 2 diabetes. Diabetic Medicine.
Crossref
Crossref
Gábor Winkler, Péter Hajós & János Tibor Kiss. (2019)
A glükagonszerű peptid-1 (GLP1) és a gyomor-bél rendszer.
GLP1-receptor-agonisták – túlértékelt gyomor-, elfelejtődött bél- („ileal brake”) hatás?
. Orvosi Hetilap 160:49, pages 1927-1934.
Crossref
Crossref
B. Guerci, B. Charbonnel, P. Gourdy, S. Hadjadj, H. Hanaire, M. Marre & B. Vergès. (2019) Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes & Metabolism 45:6, pages 528-535.
Crossref
Crossref
Solomon Nuhoho, Jatin Gupta, Brian Bekker Hansen, Mary Fletcher-Louis, Tam Dang-Tan & Abby Paine. (2019) Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. Diabetes Therapy 10:6, pages 2183-2199.
Crossref
Crossref
Lawrence Blonde, Julio Rosenstock, Stefano Del Prato, Robert Henry, Naim Shehadeh, Juan Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji & Vanita R. Aroda. (2019) Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care 42:11, pages 2108-2116.
Crossref
Crossref
Anastasia-Stefania Alexopoulos & John B. Buse. (2019) Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism 98, pages 104-111.
Crossref
Crossref
Joan Khoo, John C. Hsiang, Ranu Taneja, Seok‐Hwee Koo, Gaik‐Hong Soon, Carmen J. Kam, Ngai‐Moh Law & Tiing‐Leong Ang. (2019) Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease. Liver International 39:5, pages 941-949.
Crossref
Crossref
Cheli Melzer-Cohen, Gabriel Chodick, Lise Lotte N. Husemoen, Nicolai Rhee, Varda Shalev & Avraham Karasik. (2019) A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes. Diabetes Therapy 10:2, pages 683-696.
Crossref
Crossref
Megumi Shiomi, Tesshu Takada, Yoichi Tanaka, Keiko Yajima, Akira Isomoto, Masaki Sakamoto & Katsuya Otori. (2019) Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists. Journal of Diabetes Investigation 10:2, pages 408-417.
Crossref
Crossref
Yehuda Handelsman, Christina Chovanes, Terry Dex, Francesco Giorgino, Neil Skolnik, Elisabeth Souhami, William Stager, Elisabeth Niemoeller & Juan Pablo Frias. (2019) Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. Journal of Diabetes and its Complications 33:3, pages 236-242.
Crossref
Crossref
Luba Yammine, Thomas R. Kosten, Maria Pimenova & Joy M. Schmitz. (2019) Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review. Diabetes Research and Clinical Practice 149, pages 78-88.
Crossref
Crossref
Leigh Perreault, Helena Rodbard, Virginia Valentine & Eric Johnson. (2019) Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Advances in Therapy 36:2, pages 265-277.
Crossref
Crossref
Abraham H Hulst, Mark P Plummer, Markus W Hollmann, J Hans DeVries, Benedikt Preckel, Adam M Deane & Jeroen Hermanides. (2018) Systematic review of incretin therapy during peri-operative and intensive care. Critical Care 22:1.
Crossref
Crossref
Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah & Hrvoje Vrazic. (2018) A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs. Diabetes Therapy 9:3, pages 1149-1167.
Crossref
Crossref